|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
FIGO Committee on Gynecologic Oncology, .
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abu-Rustum NR, Yashar CM, Arend R, Barber
E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA,
et al: NCCN guidelines® insights: Cervical cancer,
version 1.2024. J Natl Compr Canc Netw. 21:1224–1233. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ebina Y, Mikami M, Nagase S, Tabata T,
Kaneuchi M, Tashiro H, Mandai M, Enomoto T, Kobayashi Y, Katabuchi
H, et al: Japan society of gynecologic oncology guidelines 2017 for
the treatment of uterine cervical cancer. Int J Clin Oncol.
24:1–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peters WA III, Liu PY, Barrett RJ II,
Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr and
Alberts DS: Concurrent chemotherapy and pelvic radiation therapy
compared with pelvic radiation therapy alone as adjuvant therapy
after radical surgery in high-risk early-stage cancer of the
cervix. J Clin Oncol. 18:1606–1613. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hosaka M, Watari H, Kato T, Odagiri T,
Konno Y, Endo D, Mitamura T, Kikawa S, Suzuki Y and Sakuragi N:
Clinical efficacy of paclitaxel/cisplatin as an adjuvant
chemotherapy for patients with cervical cancer who underwent
radical hysterectomy and systematic lymphadenectomy. J Surg Oncol.
105:612–616. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matoda M, Takeshima N, Michimae H, Iwata
T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H,
et al: Postoperative chemotherapy for node-positive cervical
cancer: Results of a multicenter phase II trial (JGOG1067). Gynecol
Oncol. 149:513–519. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li S, Hu T, Chen Y, Zhou H, Li X, Cheng X,
Yang R, Wang S, Xie X and Ma D: Adjuvant chemotherapy, a valuable
alternative option in selected patients with cervical cancer. PLoS
One. 8:e738372013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weng D, Xiong H, Zhu C, Wan X, Chen Y,
Wang X, Zhang Y, Jiang J, Zhang X, Gao Q, et al: Adjuvant
chemotherapy versus adjuvant concurrent chemoradiotherapy after
radical surgery for early-stage cervical cancer: A randomized,
non-inferiority, multicenter trial. Front Med. 17:93–104. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Yu R, Zhang L, Wang R and Xiao L:
Chemotherapy versus chemoradiotherapy for FIGO stages IB1 and IIA1
cervical squamous cancer patients with lymphovascular space
invasion: A retrospective study. BMC Cancer. 22:2022022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang F, Xing P, Song F, Du X, Wang G,
Chen K and Yang J: The role of T-box genes in the tumorigenesis and
progression of cancer. Oncol Lett. 12:4305–4311. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bilican B and Goding CR: Cell cycle
regulation of the T-box transcription factor tbx2. Exp Cell Res.
312:2358–2366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abrahams A, Parker MI and Prince S: The
T-box transcription factor Tbx2: Its role in development and
possible implication in cancer. IUBMB Life. 62:92–102. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu R, Deng J, Li C, Xu C, Cui ZH and Zhao
J: Clinical significance of TBX2 in esophageal squamous cell
carcinomas and its role in cell migration and invasion. Eur Rev Med
Pharmacol Sci. 24:3062–3068. 2020.PubMed/NCBI
|
|
15
|
Ding N, Zhang T, Yu X and Zhuang S: T-box
transcription factor 2 enhances chemoresistance of endometrial
cancer by mediating NRF2 expression. Curr Protein Pept Sci.
23:563–570. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vance KW, Carreira S, Brosch G and Goding
CR: Tbx2 is overexpressed and plays an important role in
maintaining proliferation and suppression of senescence in
melanomas. Cancer Res. 65:2260–2268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nandana S, Tripathi M, Duan P, Chu CY,
Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, et
al: Bone metastasis of prostate cancer can be therapeutically
targeted at the TBX2-WNT signaling axis. Cancer Res. 77:1331–1344.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang Y, Li Z, Zhong Q, Li G, Zhang Y and
Huang Z: Association of TBX2 and P21 expression with
clinicopathological features and survival of laryngeal squamous
cell carcinoma. Int J Clin Exp Med. 7:5394–5402. 2014.PubMed/NCBI
|
|
19
|
Zhang Z and Guo Y: High TBX2 expression
predicts poor prognosis in non-small cell lung cancer. Neoplasma.
61:476–480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H, Liu BO, Liu A, Li K and Zhao H:
T-box 2 expression predicts poor prognosis in gastric cancer. Oncol
Lett. 10:1689–1693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahlamäki EH, Bärlund M, Tanner M,
Gorunova L, Höglund M, Karhu R and Kallioniemi A: Frequent
amplification of 8q24, 11q, 17q, and 20q-specific genes in
pancreatic cancer. Genes Chromosomes Cancer. 35:353–358. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis E, Teng H, Bilican B, Parker MI, Liu
B, Carriera S, Goding CR and Prince S: Ectopic Tbx2 expression
results in polyploidy and cisplatin resistance. Oncogene.
27:976–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wansleben S, Davis E, Peres J and Prince
S: A novel role for the anti-senescence factor TBX2 in DNA repair
and cisplatin resistance. Cell Death Dis. 4:e8462013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ismail A and Bateman A: Expression of TBX2
promotes anchorage-independent growth and survival in the
p53-negative SW13 adrenocortical carcinoma. Cancer Lett.
278:230–240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Inoue Y, Fukuda T, Nanno S, Awazu Y,
Shimomura M, Matsubara H, Yamauchi M, Yasui T and Sumi T: T-box 2
expression is a useful indicator of the response to neoadjuvant
chemotherapy for patients with locally advanced uterine cervical
squamous cell carcinoma. Oncol Lett. 22:7552021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tasaka R, Fukuda T, Shimomura M, Inoue Y,
Wada T, Kawanishi M, Yasui T and Sumi T: TBX2 expression is
associated with platinum-sensitivity of ovarian serous carcinoma.
Oncol Lett. 15:3085–3090. 2018.PubMed/NCBI
|
|
27
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jacobs JJ, Keblusek P, Robanus-Maandag E,
Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ,
Koh EY, Daley GQ and van Lohuizen M: Senescence bypass screen
identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified
in a subset of human breast cancers. Nat Genet. 26:291–299. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fujiwara K, Daido S, Yamamoto A, Kobayashi
R, Yokoyama T, Aoki H, Iwado E, Shinojima N, Kondo Y and Kondo S:
Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1
in apoptosis and autophagy. J Biol Chem. 283:388–397. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Zhu LJ, Yang YC, Wang ZX and Wang
R: MiR-224 promotes the chemoresistance of human lung
adenocarcinoma cells to cisplatin via regulating G1/S transition
and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer.
111:339–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Awazu Y, Fukuda T, Noda T, Uchikura E,
Nanno S, Imai K, Yamauchi M, Yasui T and Sumi T: CLPTM1L expression
predicts recurrence of patients with intermediate- and high-risk
stage IB-IIB cervical cancer undergoing radical hysterectomy
followed by TP as adjuvant chemotherapy. Oncol Lett. 26:3532023.
View Article : Google Scholar : PubMed/NCBI
|
